In bioprocess development, speed isn't just about moving faster, it's about generating better data sooner. The sooner a system is installed, the sooner your team can begin making informed decisions.
That is why evaluating a bioreactor platform should go beyond technical specifications. Every week spent waiting for equipment, configuring hardware, manually programming processes, or managing fragmented analysis workflows delays the insights that move your program forward. Shared gas-control infrastructure and time-intensive assay design can add further complexity, limiting experimental flexibility and slowing the path from data to decision.
Stratyx™ 250 is designed to eliminate these delays. With delivery in 2–4 weeks and installation in less than a day, teams can begin running experiments quickly. Each reactor features a dedicated four-gas mass flow controller, enabling independent and precise gas control for greater flexibility and consistency across experimental conditions. Cloud-connected monitoring and cloud-based analysis centralize run data, improve visibility, and allow scientists to evaluate results from anywhere.
AI-assisted tools further simplify experimental and assay design, automation programming, and data analysis, reducing manual effort and accelerating the progression from scientific question to actionable insight. Together, these capabilities enable teams to begin running experiments in hours, not weeks, while generating the reliable data needed to make faster, more confident decisions.
But accelerating the timeline is only half the story.
A recent side-by-side study with Bionova Scientific compared Stratyx 250 against a conventional 250 mL bioreactor platform using an identical fed-batch CHO process. The results demonstrated comparable viable cell density, metabolite profiles, and product quality between the systems. At the same time, Stratyx consistently achieved higher cell viability and higher IgG titer, with the authors attributing these improvements to Stratyx's independent gassing architecture and precise feeding capabilities. Read the Whitepaper
The study concluded that Stratyx delivers more than operational efficiency, it also provides a viable, high-performance scale-down model. Researchers observed higher cell viability and product titer while maintaining comparable product quality, giving scientists confidence that faster workflows don't require compromising scientific outcomes.
The result is a powerful combination: a platform that gets your team to meaningful data sooner, and helps generate better data once you're there. In fact, many teams can install Stratyx and complete multiple experiments before an alternative system has even been delivered. See the side by side comparison below.